XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.1
SHAREHOLDERS' EQUITY
 6 Months Ended
Feb. 28, 2025
Equity [Abstract]  
SHAREHOLDERS' EQUITY SHAREHOLDERS' EQUITY
Shares Outstanding

Shares of Company's common stock outstanding for the three and six months ended February 28, 2025, and February 29, 2024, were as follows:
Three Months EndedSix Months Ended
(in thousands)February 28, 2025February 29, 2024February 28, 2025February 29, 2024
Common stock outstanding, beginning of period20,085 19,966 20,051 19,938 
Common stock issued during the period26 18 60 46 
Common stock outstanding, end of period20,111 19,984 20,111 19,984 
The following table summarizes information about stock options:
(in thousands, except per share and weighted-average amounts)
Activity for the six months ended February 28, 2025Number of
Options 		Weighted-Average
Exercise Price
Per Share		Weighted-Average
Remaining
Contractual Life
Outstanding, August 31, 20241,906 $37.64 6.91 years
Granted356 33.18 
Exercised(71)13.50 
Canceled/Forfeited(97)42.94 
Outstanding, February 28, 20252,094 $37.46 7.05 years
Vested and Exercisable, February 28, 2025990 $35.16 5.31 years
Vested and Expected to Vest, February 28, 20251,997 $37.49 6.95 years
The total grant-date fair value of nonvested stock options as of February 28, 2025, was $21.1 million and is amortizable over a weighted-average period of 3.20 years.
The fair value of these options was estimated at the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-valuation model was developed for use in estimating the fair value of stock options, which do not have vesting restrictions and are fully transferable. In addition, option-valuation models require the input of highly subjective assumptions, including the expected stock price volatility.
The following table summarizes the fair value of the options, including both ISOs and NQSOs, granted during the six months ended February 28, 2025, and for the fiscal year ended August 31, 2024:
(in thousands, except weighted-average amounts)Six Months Ended February 28, 2025Fiscal Year 2024
Estimated fair value of awards granted$6,190 $11,902 
Unvested forfeiture rate6.26 %5.53 %
Weighted-average grant price$33.18 $40.76 
Weighted-average market price$33.18 $40.76 
Weighted-average volatility46.93 %44.63 %
Weighted-average risk-free rate3.95 %4.77 %
Weighted-average dividend yield0.00 %0.59 %
Weighted-average expected life6.61 years6.59 years
The exercise prices for the options outstanding at February 28, 2025, ranged from $6.85 to $66.14 per share, and the information relating to these options is as follows:
(in thousands except prices and weighted-average amounts)
Exercise Price Per ShareAwards OutstandingAwards Exercisable
LowHighQuantityWeighted -Average
Remaining
Contractual
Life		Weighted-Average
Exercise
Price		QuantityWeighted-Average
Remaining
Contractual
Life		Weighted-Average
Exercise
Price
$6.85 $9.77 93 0.99 years$9.71 93 0.99 years$9.71 
$9.78 $18.76 128 1.99 years$10.08 128 1.99 years$10.08 
$18.77 $33.40 498 8.02 years$31.07 147 4.16 years$26.05 
$33.41 $47.63 1,101 7.90 years$41.36 429 7.36 years$41.32 
$47.64 $66.14 274 6.32 years$55.65 193 5.89 years$57.33 
  2,094 7.05 years$37.46 990 5.31 years$35.16 
During the three and six months ended February 28, 2025, and February 29, 2024, respectively, we issued 3,935 and 8,895 shares of stock valued at $0.1 million and $0.3 million, respectively, to our nonmanagement directors as compensation for board-related duties.
The Company's par-value common stock and additional paid-in capital as of February 28, 2025, were $11 thousand and $156.2 million, respectively.
Share Repurchases
No share repurchases were made during the three and six months ended February 28, 2025,